Jennifer R. Brown, MD, PhD, highlights newly FDA approved Bruton’s tyrosine kinase inhibitor (BTKi) monotherapy therapies for the treatment of CLL (chronic lymphocytic leukemia).
Examining the Role of Frontline BTKi Monotherapy in CLL
Citing results from recent trials, Jennifer R. Brown, MD, PhD, compares patient tolerability levels of ibrutinib, zanubrutinib, and acalabrutinib.
Jennifer R. Brown, MD, PhD, suggests alternative treatments for patients who experience severe adverse-events from ibrutinib.
The shortcomings physicians face in combatting CLL (chronic lymphocytic leukemia) are discussed, in addition to what the high-level updates from the ELEVATE-RR press release may reveal regarding future treatments for CLL.